Elan raises $381M; Cornerstone drug gets a PDUFA date; Insights on breast cancer from University of Kentucky;

@FierceBiotech: Regulators start thinking creatively about new approval pathway. Report | Follow @FierceBiotech

@JohnCFierce: Troubled Marina Biotech does a DNAi discovery deal with scads of biobucks involved. Release | Follow @JohnCFierce

@RyanMFierce: An interesting skeptic's take on the promise of DNA sequencing personalizing healthcare. Story | Follow @RyanMFierce

@FierceMedDev: Chicago hospital doctors say iPads raise their efficiency, via Fox News. Article | Follow @FierceMedDev

> Elan has raised $381 million from the sale of Alkermes stock. Report

> The FDA has accepted Cornerstone Therapeutics' NDA for a drug that treats hyponatremia, abnormally low blood sodium levels often seen in heart failure patients. The agency set Oct. 29 as the PDUFA date. Story

> BioFocus and Argenta have forged a multi-year collaboration agreement with AstraZeneca to find new compounds for AZ's research programs in respiratory and inflammatory diseases. Release

Pharma News

@FiercePharma: Interesting Bloomberg piece on Austrian who made his millions off drug-price differences in U.K. and EU. Article | Follow @FiercePharma

> Sanofi to shutter Plavix-producing U.K. plant. Item

> Novo seen to benefit from Pfizer-Biocon split. Report

> Judge chooses lead lawyers in Actos litigation. News

> Bayer eyes 16% pharma growth on new meds. Story

> Austrian racks up millions from parallel trade in EU. More

Medical Device News

> Medtronic faces more shareholder ire over Infuse. More

> ViewRay closes $45M Series C. News

> Boston Sci, Vodafone partner on mobile health monitoring. Story

Biomarkers News

> Inflammatory protein marks heart disease. Item

> Researchers find 5 Crohn's disease markers in Ashkenazi Jews. Story

> New biomarkers could mean a blood test for autism. More

> Chikungunya could identify high-risk patients. Article

> Genetic mutation links with age in neuroblastoma. Story

> Nuclea Bio hunts prostate markers. Item

Drug Delivery News

> Kala Pharmaceuticals, co-launched by MIT's Langer, snags $6.2M. News

> InflammaGen drug delivery weapon targets self-digestion in Phase II trial. Article

> Scientists harness molecular 'transporter' to boost drug delivery prowess. Story

And Finally… Investigators at the University of Kentucky say they have gained new insights into developing treatments for triple-negative breast cancer. They add they've found a master switch involved in the spread of cancer cells. Release

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.